Madrigal Pharmaceuticals, Inc. (MDGL) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は BAY CITY CAPITAL LLC 2,310,521 株保有. その他の主要保有者には Kovner Bruce および Taub Rebecca.
過去12ヶ月間にインサイダーは 30 件の取引を実施 MDGL 株式 — 13 件の買い (評価額 $20.93M) および 12 件の売り (評価額 $4.63M). インサイダーの買いが売りを上回っており、会社の見通しに対する自信の表れかもしれません.
MDGL インサイダー保有状況
最大保有者
BAY CITY CAPITAL LLC
2,310,521 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Bay City Capital Llc |
10 Percent Owner |
2,310,521 |
2020-12-01 |
|
| 2 |
Kovner Bruce |
10 Percent Owner |
837,021 |
2015-12-08 |
|
| 3 |
Taub Rebecca |
Director |
452,213 |
2026-03-06 |
|
| 4 |
Vukovic Vojo |
SVP, Chief Medical Officer |
132,300 |
2015-10-06 |
|
| 5 |
Mcmahon Arthur |
SVP, Human Resources |
126,768 |
2015-03-04 |
|
| 6 |
Whitaker Anne Clem |
President and CEO |
100,000 |
2015-03-04 |
|
| 7 |
Ramachandra Sumant |
President, R&d |
75,000 |
2013-03-13 |
|
| 8 |
Singh Amar |
Sr. VP, Chief Business Officer |
73,505 |
2013-03-07 |
|
| 9 |
Ehrlich Keith S |
VP, Fin. and Admin., CFO |
66,985 |
2014-03-05 |
|
| 10 |
Schor Chen |
Former President and CEO |
37,178 |
2016-07-22 |
|
| 11 |
Schneebaum Marc R |
Chief Financial Officer |
32,000 |
2021-02-23 |
|
| 12 |
Bernitz Steven B |
SVP, Corporate Development |
25,000 |
2013-12-20 |
|
| 13 |
Kufe Donald W |
Director |
20,000 |
2015-07-06 |
|
| 14 |
Reardon William S |
Director |
20,000 |
2015-07-06 |
|
| 15 |
Wilson Robert N |
Director |
20,000 |
2015-07-06 |
|
| 16 |
Sibold William John |
President and CEO |
18,743 |
2026-03-06 |
|
| 17 |
Morenstein Scott D |
Director |
17,857 |
2016-01-05 |
|
| 18 |
Rieder Wendy E |
Former SVP, Gen. Counsel |
17,730 |
2016-07-22 |
|
| 19 |
Sukhija Remy |
Chief Commercial Officer |
15,001 |
2023-01-18 |
|
| 20 |
Bahcall Safi R |
President and CEO |
15,000 |
2014-02-13 |
|
最近の取引 (過去12ヶ月)
| 日付 |
氏名 |
役職 |
種類 |
株数 |
株価 |
価値 |
| 2026-03-06 |
Kelley Shannon T |
General Counsel |
情報に基づく売り |
360 |
$431.94 |
$155.5K |
| 2026-03-04 |
Kelley Shannon T |
General Counsel |
RSU 付与（制限付株式） |
5,022 |
$434.80 |
$2.18M |
| 2026-03-06 |
Huntsman Carole |
Chief Commercial Officer |
情報に基づく売り |
419 |
$431.94 |
$180.98K |
| 2026-03-04 |
Huntsman Carole |
Chief Commercial Officer |
RSU 付与（制限付株式） |
4,986 |
$434.80 |
$2.17M |
| 2026-03-04 |
Soergel David |
Chief Medical Officer |
RSU 付与（制限付株式） |
5,467 |
$434.80 |
$2.38M |
| 2026-03-06 |
Dier Mardi |
EVP and CFO |
情報に基づく売り |
40 |
$437.65 |
$17.51K |
| 2026-03-04 |
Dier Mardi |
EVP and CFO |
RSU 付与（制限付株式） |
6,519 |
$434.80 |
$2.83M |
| 2026-03-06 |
Sibold William John |
President and CEO |
情報に基づく売り |
1,663 |
$431.94 |
$718.32K |
| 2026-03-04 |
Sibold William John |
President and CEO |
RSU 付与（制限付株式） |
18,743 |
$434.80 |
$8.15M |
| 2026-03-06 |
Taub Rebecca |
Director |
情報に基づく売り |
491 |
$431.94 |
$212.08K |
| 2026-03-02 |
Dier Mardi |
EVP and CFO |
情報に基づく売り |
1,183 |
$427.21 |
$505.39K |
| 2026-02-23 |
Levy Richard S |
Director |
オプション行使（売却） |
2,500 |
$7.36 |
$18.4K |
| 2026-01-26 |
Huntsman Carole |
Chief Commercial Officer |
情報に基づく売り |
570 |
$494.59 |
$281.92K |
| 2026-01-26 |
Sibold William John |
President and CEO |
情報に基づく売り |
1,577 |
$492.42 |
$776.55K |
| 2026-01-26 |
Levy Richard S |
Director |
オプション行使（売却） |
4,000 |
$16.46 |
$65.84K |
| 2026-01-26 |
Taub Rebecca |
Director |
情報に基づく売り |
647 |
$492.42 |
$318.6K |
| 2026-01-15 |
Thakkar Rita |
Chief Accounting Officer |
RSU 付与（制限付株式） |
1,826 |
$495.88 |
$905.48K |
| 2026-01-12 |
Thakkar Rita |
Officer |
不明 |
- |
- |
- |
| 2026-01-20 |
Kelley Shannon T |
General Counsel |
情報に基づく売り |
429 |
$501.40 |
$215.1K |
| 2026-01-20 |
Taub Rebecca |
Director |
情報に基づく売り |
2,238 |
$490.77 |
$1.1M |
| 2026-01-09 |
Taub Rebecca |
Director |
情報に基づく売り |
271 |
$534.18 |
$144.76K |
| 2026-01-09 |
Friedman Paul A |
Director |
オプション行使（売却） |
24,520 |
$15.80 |
$387.42K |
| 2025-06-20 |
Daly James M |
Director |
RSU 付与（制限付株式） |
1,290 |
$285.73 |
$368.59K |
| 2025-06-20 |
Levy Richard S |
Director |
RSU 付与（制限付株式） |
1,290 |
$285.73 |
$368.59K |
| 2025-06-20 |
Fouse Jacqualyn A |
Director |
RSU 付与（制限付株式） |
366 |
$285.73 |
$104.58K |
